GSK2132231A
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GSK2132231A, covering 2019-09-27 to 2019-09-27. Get the full timeline:
Most recent: Clinical Trial Update: Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma [Phase 2]